Thirty-four of 58 LG-NHL patients had received anti-lymphoma treatment including rituximab, obinutuzumab alone or in combination with chemotherapy, or Bruton Tyrosine Kinase (BTK) inhibitors at the time of their vaccinations. Here, BTK is linked to non-Hodgkin lymphoma.